Jul 28, 2020 · Therefore, targeting EZH2 for cancer therapy is a hot research topic now and different types of EZH2 inhibitors have been developed. In this review, we summarize the …

The enhancer of zeste homolog 2 (EZH2) is encoded by the Enhancer of zeste 2 polycomb repressive complex 2 subunit gene. EZH2 is involved in the cell cycle, DNA damage repair, …

Mar 30, 2025 · EZH2 (Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit) is a Protein Coding gene. Diseases associated with EZH2 include Weaver Syndrome and Prc-2 …

Functions of EZH2 in cells proliferation, apoptosis, and senescence have been identified. Its important roles in the pathophysiology of cancer are now widely concerned. Therefore, …

Dec 23, 2013 · EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. …

EZH2 is involved in global transcriptional repression, mainly targeting tumor suppressor genes. EZH2 is commonly overexpressed in cancer and shows activating mutations in subtypes of …

Nov 27, 2024 · EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity …

Feb 4, 2016 · Roberts and Kim discuss the mechanistic roles played by EZH2 in cancer as well as efforts to therapeutically target this epigenetic modifier.

EZH2 orchestrates the regulation of the innate and adaptive immune systems of the tumor microenvironment (TME). Profound epigenetic and transcriptomic changes induced by EZH2 …

Jan 31, 2025 · Osteolytic bone disease is a complication that affects 80% of patients with multiple myeloma. Here, authors show that inhibition of EMP1 due to EZH2 activation results in …